about
Detecting phase separation of freeze-dried binary amorphous systems using pair-wise distribution function and multivariate data analysis.Quality by design approach in the optimization of the spray-drying process.Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.Emerging trends in the stabilization of amorphous drugs.Refining stability and dissolution rate of amorphous drug formulations.Unintended and in situ amorphisation of pharmaceuticals.Recent advances in co-amorphous drug formulations.Correlation between calculated molecular descriptors of excipient amino acids and experimentally observed thermal stability of lysozyme.Influence of variation in molar ratio on co-amorphous drug-amino acid systems.Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.Large-Scale Biophysical Evaluation of Protein PEGylation Effects: In Vitro Properties of 61 Protein Entities.Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.Design of experiments-based monitoring of critical quality attributes for the spray-drying process of insulin by NIR spectroscopy.Multivariate analysis of phenol in freeze-dried and spray-dried insulin formulations by NIR and FTIRTowards a robust water content determination of freeze-dried samples by near-infrared spectroscopy.Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin.Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface.Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions.Fuzzy Logic-based expert system for evaluating cake quality of freeze-dried formulations.Formation of mannitol hemihydrate in freeze-dried protein formulations--a design of experiment approach.Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.Classification of lyophilised mixtures using multivariate analysis of NIR spectra.Role of excipients in the quantification of water in lyophilised mixtures using NIR spectroscopy.Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix.In situ amorphisation of indomethacin with Eudragit® E during dissolution.Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin.The significance of the amorphous potential energy landscape for dictating glassy dynamics and driving solid-state crystallisation.Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ.Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.
P50
Q30656382-4F962881-AF91-4A4C-86FE-29D72F1F38DFQ33806245-1B96F4E8-D2C2-44E1-90F7-E6EC9FCB1D98Q37579215-AD529336-B37E-4C8D-8458-2325479EA272Q38008517-8832E165-0179-4FDA-A9EF-7662ED30A956Q38206296-78FA8721-6C8C-487C-AADC-996263289D64Q38685076-C986D116-1D6C-4F57-BF65-C7FECBF76417Q38710042-2351DC17-13CE-48CB-A405-7BE0EC6C560FQ38881154-E312E357-A8B6-4D22-9B37-9940405B3A15Q39638481-4A56E483-00E5-4DD0-827D-7D1103FADC09Q39808123-94B799BD-85A4-4976-AACB-36169C54AACEQ39864701-05C04D1C-E1A5-4A50-B1D1-9EC602EAC300Q40375864-180BD7F6-079E-44EF-8141-2ADD0E48B1AAQ40854029-25AF508E-5DF5-4EAB-BFAE-F014CA2B508EQ42121711-8AFA1989-A2AD-453E-A304-BDDD300FCD5FQ42278205-228CFF86-179F-4AC9-9A5B-D9EEA13990B8Q42923690-0DCCF623-7EA2-4177-82E8-9A2B6ADDBD5EQ42936240-34129950-3281-43D4-8498-FA038DD37567Q43753649-FAE1F8EA-1D3B-4C2E-A5C2-560852D8EFC7Q44752312-25F0552C-BE45-4F83-9AB1-325B4D047D5FQ44798428-4B5BF7D3-17ED-46EA-8558-98B19F1EF0DBQ44953191-64C2C2BF-DAC2-4362-8CC3-BE81453E5B5BQ45403649-2F7596B5-5B63-4BA4-93C8-A52F5F276EE1Q45811011-18386707-AB0E-4109-B60F-6DC32A10628CQ45939827-B82B5567-AB16-43D4-B909-5CC673073103Q46121839-FB704212-1608-44A6-8C00-3CF44287615AQ46318738-EF5BCF81-AC4B-4EE9-A3A6-9E0368EAB651Q46370480-4819A93F-5CA6-46D6-B0CB-B00FE17B3603Q46546738-4C940DEF-85EB-4E48-8D9B-E8AA4B0A6E2EQ47183480-08C841CC-5247-4884-965E-CFFD670B37C6Q47388871-F0BA30FD-07EE-48BE-BE46-0F177CD756CAQ47712752-9A7F6829-1829-4639-8C9E-F8C1C71FF39FQ47718326-6F3BAE5F-6BAD-450A-BCCD-E73F789A299FQ47813276-87609E45-2E04-415D-AF8D-33067860014AQ47865775-A920C6A1-B42F-4F3C-97A4-032C35D3B952Q47870602-CD799894-19B2-46E9-8DE5-18D6D5576DD7Q48009158-474C16B5-9884-4258-AC99-4CA90799D96EQ49092618-3278740B-8EE9-4DA3-826D-0BDC9DCDAD08Q50258918-C4D5CBE1-FF11-4FF4-BC5C-5BF201345F79Q50282539-2C553F91-BC35-417C-93BD-BD1F2C47FA69Q50756353-286F0280-1C6D-447A-8C9F-3BD27F07FEAC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Holger Grohganz
@ast
Holger Grohganz
@en
Holger Grohganz
@es
Holger Grohganz
@nl
Holger Grohganz
@sl
type
label
Holger Grohganz
@ast
Holger Grohganz
@en
Holger Grohganz
@es
Holger Grohganz
@nl
Holger Grohganz
@sl
prefLabel
Holger Grohganz
@ast
Holger Grohganz
@en
Holger Grohganz
@es
Holger Grohganz
@nl
Holger Grohganz
@sl
P106
P1153
6507780984
P21
P31
P496
0000-0002-0482-1397